Benjamin H. Lowentritt, MD, FACS, Discusses Future Analyses for the Phase 3 SPOTLIGHT Trial in Recurrent Prostate Cancer

Video

Future focuses following the phase 3 SPOTLIGHT trial will include identifying sites of recurrence and different intensity levels for 18F-rhPSMA-7.3 in suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.

In an interview with CancerNetwork® during the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin H. Lowentritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, highlighted next steps for the phase 3 SPOTLIGHT study (NCT04186845), which examined the impact of clinical factors on detection rates of 18F-rhPSMA-7.3 in suspected recurrent prostate cancer. In terms of future analyses, Lowentritt indicated that assessing sites of disease recurrence and levels of intensity will be areas of focus.

Transcript:

The SPOTLIGHT trial data are really just coming to light and being reported. We're continuing to look at different subgroup analyses. [We are] also really drilling into some of the sites of recurrence and identifying where and when this may be most helpful. [We are] evaluating different levels of intensity, the [standardized uptake value], and other things within the actual imaging reports and how that may predict sites of disease. There is certainly continuing to be a lot of work done with the data from the SPOTLIGHT trial, which was only recently completed.

Reference

Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Recent Videos
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Related Content